Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Authors
Laura Torrecillas (ORCID: https://orcid.org/0000-0003-1302-4389)
Francisco Ayala (ORCID: https://orcid.org/0000-0001-6311-920X)
Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Laura Torrecillas, Francisco Ayala, Federico Rojo, Begoña Bermejo et al.
Topics
Advanced Breast Cancer Therapies
article
Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Laura Torrecillas, Francisco Ayala, Federico Rojo, Begoña Bermejo, José Bines, Roberto Torres, Agustí Barnadas, José Á. García-Sáenz, Antonio Llombart‐Cussac, Lourdes Calvo, Raúl Rincón, Jesús Herránz, Juan de la Haba-Rodríguez, Ángel Guerrero‐Zotano, José Manuel Baena-Cañada, Henry Gómez, María Rodríguez de la Borbolla, Manuel Ruíz-Borrego, Rosalía Caballero, Sandra Pérez‐Buira, Miguel Martín, Carlos H. Barrios, Partha S. Ray, Clive R. Taylor